<?xml version="1.0" encoding="UTF-8"?>
<p id="Par28">Although cellular immunity was reported to be compromised among long-term LVAD recipients, [
 <xref ref-type="bibr" rid="CR71">71</xref>, 
 <xref ref-type="bibr" rid="CR72">72</xref>] there is no clear evidence suggesting that they are at increased risk of acquiring the virus. It is also known that the inflammatory profile is significantly altered in HF patients supported by LVAD therapy, who generally have elevated cytokines [
 <xref ref-type="bibr" rid="CR73">73</xref>]. This should be taken into consideration when clinically evaluating LVAD patients presenting with COVID-19 or utilizing their inflammatory and cardiac biomarkers for treatment or prognosis.
</p>
